Product Data Sheet

KIRA-7

Cat. No.: HY-124646

CAS No.: 1937235-76-1

Molecular Formula: $C_{27}H_{23}FN_6O$ Molecular Weight: 466.51

Target: IRE1

Pathway: Cell Cycle/DNA Damage

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (214.36 mM; Need ultrasonic)

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.1436 mL	10.7179 mL	21.4358 mL
Stock Solutions	5 mM	0.4287 mL 2.1436 mL 4	4.2872 mL	
	10 mM	0.2144 mL	1.0718 mL	2.1436 mL

Please refer to the solubility information to select the appropriate solvent.

\mathbf{DIO}	ו אכו	~ 1	ACTI	MTM
BIU		U.AI	ACTI	VIIY

Description	KIRA-7, an imidazopyrazine compound, binds the IRE1 α kinase (IC50 of 110 nM) to allosterically inhibit its RNase activity. KIRA-7 has an anti-fibrotic effect ^[1] .
IC ₅₀ & Target	IC50: 110 nM (IRE1 α kinase) $^{[1]}$
In Vitro	KIRA-7 can inhibit XBP1 splicing in the alveolar epithelial cell line $MLE12^{[1]}$. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	KIRA-7 (5 mg/kg; intraperitoneal injection; daily for 14 days; C57BL6 mice) treatment results in decreased spliced XBP1 and ATF4, compared to bleomycin exposed mice treated with vehicle. Likewise, mRNA levels of BiP and CHOP are significantly elevated after Bleomycin exposure, and treatment of Bleomycin-exposed mice with KIRA-7 decreased these levels. mRNA levels of collagen 1A1 and fibronectin are both significantly decreased by KIRA-7 treatment ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL6 mice (12 weeks of age) with Bleomycin (1.5 units/kg) ^[1]	
Dosage:	5 mg/kg	
Administration:	Intraperitoneal injection; daily; for 14 days	
Result:	Resulted in decreased spliced XBP1 and ATF4. Likewise, mRNA levels of BiP and CHOP were significantly decreased.	

REFERENCES

 $[1]. Thamsen \ M, et \ al. \ Small \ molecule \ inhibition \ of \ IRE1\alpha \ kinase/RNase \ has \ anti-fibrotic \ effects \ in \ the \ lung. \ PLoS \ One. \ 2019 \ Jan \ 9;14(1):e0209824.$

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com